369 related articles for article (PubMed ID: 15209500)
1. Structural determinants of RXPA380, a potent and highly selective inhibitor of the angiotensin-converting enzyme C-domain.
Georgiadis D; Cuniasse P; Cotton J; Yiotakis A; Dive V
Biochemistry; 2004 Jun; 43(25):8048-54. PubMed ID: 15209500
[TBL] [Abstract][Full Text] [Related]
2. Investigating the domain specificity of phosphinic inhibitors RXPA380 and RXP407 in angiotensin-converting enzyme.
Kröger WL; Douglas RG; O'Neill HG; Dive V; Sturrock ED
Biochemistry; 2009 Sep; 48(35):8405-12. PubMed ID: 19658433
[TBL] [Abstract][Full Text] [Related]
3. Combined use of selective inhibitors and fluorogenic substrates to study the specificity of somatic wild-type angiotensin-converting enzyme.
Jullien ND; Cuniasse P; Georgiadis D; Yiotakis A; Dive V
FEBS J; 2006 Apr; 273(8):1772-81. PubMed ID: 16623712
[TBL] [Abstract][Full Text] [Related]
4. The structure of testis angiotensin-converting enzyme in complex with the C domain-specific inhibitor RXPA380.
Corradi HR; Chitapi I; Sewell BT; Georgiadis D; Dive V; Sturrock ED; Acharya KR
Biochemistry; 2007 May; 46(18):5473-8. PubMed ID: 17439247
[TBL] [Abstract][Full Text] [Related]
5. Positional-scanning combinatorial libraries of fluorescence resonance energy transfer peptides for defining substrate specificity of the angiotensin I-converting enzyme and development of selective C-domain substrates.
Bersanetti PA; Andrade MC; Casarini DE; Juliano MA; Nchinda AT; Sturrock ED; Juliano L; Carmona AK
Biochemistry; 2004 Dec; 43(50):15729-36. PubMed ID: 15595828
[TBL] [Abstract][Full Text] [Related]
6. Development of domain-selective angiotensin I-converting enzyme inhibitors.
Redelinghuys P; Nchinda AT; Sturrock ED
Ann N Y Acad Sci; 2005 Nov; 1056():160-75. PubMed ID: 16387685
[TBL] [Abstract][Full Text] [Related]
7. Synthesis and molecular modeling of a lisinopril-tryptophan analogue inhibitor of angiotensin I-converting enzyme.
Nchinda AT; Chibale K; Redelinghuys P; Sturrock ED
Bioorg Med Chem Lett; 2006 Sep; 16(17):4616-9. PubMed ID: 16784843
[TBL] [Abstract][Full Text] [Related]
8. Different contributions of the angiotensin-converting enzyme C-domain and N-domain in subjects with the angiotensin-converting enzyme II and DD genotype.
van Esch JH; van Gool JM; de Bruin RJ; Payne JR; Montgomery HE; Hectors M; Deinum J; Dive V; Jan Danser AH
J Hypertens; 2008 Apr; 26(4):706-13. PubMed ID: 18327080
[TBL] [Abstract][Full Text] [Related]
9. The influence of angiotensin converting enzyme mutations on the kinetics and dynamics of N-domain selective inhibition.
Lubbe L; Sewell BT; Sturrock ED
FEBS J; 2016 Nov; 283(21):3941-3961. PubMed ID: 27636235
[TBL] [Abstract][Full Text] [Related]
10. Roles of the two active sites of somatic angiotensin-converting enzyme in the cleavage of angiotensin I and bradykinin: insights from selective inhibitors.
Georgiadis D; Beau F; Czarny B; Cotton J; Yiotakis A; Dive V
Circ Res; 2003 Jul; 93(2):148-54. PubMed ID: 12805239
[TBL] [Abstract][Full Text] [Related]
11. Novel ketomethylene inhibitors of angiotensin I-converting enzyme (ACE): inhibition and molecular modelling.
Redelinghuys P; Nchinda AT; Chibale K; Sturrock ED
Biol Chem; 2006 Apr; 387(4):461-6. PubMed ID: 16606345
[TBL] [Abstract][Full Text] [Related]
12. Development of potent and selective phosphinic peptide inhibitors of angiotensin-converting enzyme 2.
Mores A; Matziari M; Beau F; Cuniasse P; Yiotakis A; Dive V
J Med Chem; 2008 Apr; 51(7):2216-26. PubMed ID: 18324760
[TBL] [Abstract][Full Text] [Related]
13. Simulated interactions between angiotensin-converting enzyme and substrate gonadotropin-releasing hormone: novel insights into domain selectivity.
Papakyriakou A; Spyroulias GA; Sturrock ED; Manessi-Zoupa E; Cordopatis P
Biochemistry; 2007 Jul; 46(30):8753-65. PubMed ID: 17605472
[TBL] [Abstract][Full Text] [Related]
14. Crystal structure of the human angiotensin-converting enzyme-lisinopril complex.
Natesh R; Schwager SL; Sturrock ED; Acharya KR
Nature; 2003 Jan; 421(6922):551-4. PubMed ID: 12540854
[TBL] [Abstract][Full Text] [Related]
15. Domain-selective ligand-binding modes and atomic level pharmacophore refinement in angiotensin I converting enzyme (ACE) inhibitors.
Tzakos AG; Gerothanassis IP
Chembiochem; 2005 Jun; 6(6):1089-103. PubMed ID: 15883972
[TBL] [Abstract][Full Text] [Related]
16. Crystal structure of the N domain of human somatic angiotensin I-converting enzyme provides a structural basis for domain-specific inhibitor design.
Corradi HR; Schwager SL; Nchinda AT; Sturrock ED; Acharya KR
J Mol Biol; 2006 Mar; 357(3):964-74. PubMed ID: 16476442
[TBL] [Abstract][Full Text] [Related]
17. RXP 407, a selective inhibitor of the N-domain of angiotensin I-converting enzyme, blocks in vivo the degradation of hemoregulatory peptide acetyl-Ser-Asp-Lys-Pro with no effect on angiotensin I hydrolysis.
Junot C; Gonzales MF; Ezan E; Cotton J; Vazeux G; Michaud A; Azizi M; Vassiliou S; Yiotakis A; Corvol P; Dive V
J Pharmacol Exp Ther; 2001 May; 297(2):606-11. PubMed ID: 11303049
[TBL] [Abstract][Full Text] [Related]
18. Selective angiotensin-converting enzyme C-domain inhibition is sufficient to prevent angiotensin I-induced vasoconstriction.
van Esch JH; Tom B; Dive V; Batenburg WW; Georgiadis D; Yiotakis A; van Gool JM; de Bruijn RJ; de Vries R; Danser AH
Hypertension; 2005 Jan; 45(1):120-5. PubMed ID: 15583077
[TBL] [Abstract][Full Text] [Related]
19. Crystal structures of highly specific phosphinic tripeptide enantiomers in complex with the angiotensin-I converting enzyme.
Masuyer G; Akif M; Czarny B; Beau F; Schwager SL; Sturrock ED; Isaac RE; Dive V; Acharya KR
FEBS J; 2014 Feb; 281(3):943-56. PubMed ID: 24289879
[TBL] [Abstract][Full Text] [Related]
20. A computational approach to the study of the binding mode of dual ACE/NEP inhibitors.
Dimitropoulos N; Papakyriakou A; Dalkas GA; Sturrock ED; Spyroulias GA
J Chem Inf Model; 2010 Mar; 50(3):388-96. PubMed ID: 20170101
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
